An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer [2]

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 256-258

  Toh, Chee Keong ^a   Lee, Pyng ^b   Chowbay, Balram ^a   Goh, Jason W K ^c   Mancer, Kent ^d   Tan, Puay Hoon ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8;

ADULT; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOLOGY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGOGASTRODUODENOSCOPY; FEVER; HELPER CELL; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LETTER; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM; MONOTHERAPY; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PRIORITY JOURNAL; THORACOCENTESIS; THORACOSCOPY; THORAX RADIOGRAPHY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PNEUMONIA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 33847021976     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600762971     Document Type: Letter

References (11)

1. Gelmon K. The taxoids: Paclitaxel and docetaxel. Lancet 1994;344:1267-72.
2. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with the toxicities of docetaxel (Taxotere). Ann Oncol 1993;4:610-1.
3. Semb KA, Aamdal S, Øian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998;16:3426-32.
4. Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 2004;287:H963-H968.
5. Kataoka K, Taniguchi H, Hasegawa Y, Kondoh Y, Kionura T, Nishiyama O, et al. Interstitial lung disease associated with gefitinib. Respir Med 2005;29 (Epub).
6. Anthony VB, Godbey SW, Kunkel SL, Hott JW, Hartman DL, Burdick MD, et al. Recruitment of inflammatory cells to the pleural space: Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993;151:7216-33.
7. Pace E, Gjomarkaj M, Melis M, Profita M, Spatafora M, Vignola AM, et al. Interleukin-8 induces lymphocyte chemotaxis into the pleural space: Role of pleural macrophages. Am J Respir Crit Care Med 1999;159:1592-9.
8. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
9. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-51.
10. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer: Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013-7.
11. Wei YQ, Hang ZB. In situ observation of lymphocyte-tumor cell interaction in human lung carcinoma. Immunol Invest 1989;18:1095-105.